CivicaScript, LLC – Trademark Portfolio

Entity Type: 16

CivicaScript, LLC holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 12 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 10 are pending. Notable registered marks include MAXRP and ABIRTEGA. The owner is based in Lehi, UT.

2912 Executive Parkway, Suite 320

Lehi, UT 84043

13 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CivicaScript, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (12 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

Frequently Asked Questions

How many trademarks does CivicaScript, LLC have?

CivicaScript, LLC has 13 U.S. trademarks filed with the USPTO. Of these, 2 registered, 10 pending, 1 abandoned.

What trademark classes does CivicaScript, LLC file in?

CivicaScript, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are CivicaScript, LLC's most well-known trademarks?

CivicaScript, LLC's registered trademark portfolio includes well-known marks such as MAXRP and ABIRTEGA. These are among 2 currently registered trademarks in the portfolio.

What is CivicaScript, LLC's trademark registration success rate?

CivicaScript, LLC has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 10 applications are pending review.